October 2020, Drugs Monitor, Page 2

(18 Oct 2020) Hydroxychloroquine- No significant reduction in incidence of COVID 19 among health workers

October 22, 2020

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1571/5929230 A randomized, double-blind, placebo-controlled clinical trial (NCT04328467) of healthcare workers with ongoing exposure to persons with SARS-CoV-2 was conducted. Participants across the United States and in the… Continue reading "(18 Oct 2020) Hydroxychloroquine- No significant reduction in incidence of COVID 19 among health workers"

(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19

October 17, 2020

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 The interim results from Solidarity trials (ISRCTN83971151 , NCT04315948 ) are presented. In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon… Continue reading "(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19"

(14 Oct 2020) Lopinavir/R- high rate of adverse events (10/23, 43%)

October 17, 2020

Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19 https://pubmed.ncbi.nlm.nih.gov/33048786/ An observational, retrospective, single-center study involving adult patients with severe SARS-CoV-2 infection was conducted. All adverse events detected in 23 patients in the Intensive Care Unit between March 15… Continue reading "(14 Oct 2020) Lopinavir/R- high rate of adverse events (10/23, 43%)"

(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety

October 17, 2020

Sarilumab use in severe SARS-CoV-2 pneumonia https://doi.org/10.1016/j.eclinm.2020.100553 Of the 53 SARS-CoV-2(pos) patients receiving Sarilumab, 39(73.6%) were treated in medical wards [66.7% with a single infusion; median PaO2/FiO2:146(IQR:120-212)] while 14(26.4%) in ICU [92.6% with a second infusion; median PaO2/FiO2: 112(IQR:100-141.5)].Within the… Continue reading "(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety"

(11 Oct 2020) Corticosteroids & Tocilizumab- combination showed beneficial effect in preventing in-hospital mortality

October 14, 2020

Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness https://doi.org/10.1016/j.ijid.2020.09.1486 From March 17 to April 7, 2020, a real-world observational retrospective analysis of consecutive hospitalized adult patients receiving TCZ to treat severe COVID-19… Continue reading "(11 Oct 2020) Corticosteroids & Tocilizumab- combination showed beneficial effect in preventing in-hospital mortality"

(11Oct 2020) Tocilizumab- Improved outcomes and effective in critical and severe patients

October 14, 2020

Efficacy and safety of tocilizumab in COVID-19 patients https://doi.org/10.18632/aging.103988 In this retrospective study, the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19) was assessed. 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with… Continue reading "(11Oct 2020) Tocilizumab- Improved outcomes and effective in critical and severe patients"

(11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality

October 12, 2020

Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients https://www.medrxiv.org/content/10.1101/2020.10.06.20208025v1 While retrospectively analyzing the complete electronic health records (EHRs) of 671 hospitalized COVID-19 patients administered either enoxaparin or unfractionated heparin,… Continue reading "(11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality"

(08 Oct 2020) Hydroxychloroquine, Ivermectin and Azithromycin- no beneficial effects of individual drugs or their combinations

October 9, 2020

Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v2 Among 5683 patients, 200 received HCT, 203 IVM, 1600 AZIT, 692 HCQ… Continue reading "(08 Oct 2020) Hydroxychloroquine, Ivermectin and Azithromycin- no beneficial effects of individual drugs or their combinations"

(08 Oct 2020) Dexamethasone- effective in improving the P/F ratio in COVID-19 patients

October 9, 2020

Comparison of efficacy of Dexamethasone and Methylprednisolone in improving P/F ratio among COVID-19 patients https://www.medrxiv.org/content/10.1101/2020.10.06.20171579v1 The efficacy of methylprednisolone and dexamethasone in reducing inflammation and improving the partial pressure of arterial oxygen and fraction of inspired oxygen (PaO2/FiO2 or P/F)… Continue reading "(08 Oct 2020) Dexamethasone- effective in improving the P/F ratio in COVID-19 patients"

(04 Oct 2020) Corticosteroids- significantly reduced mortality in severe COVID patients

October 5, 2020

Corticosteroid pulses for hospitalized patients with COVID-19. Effects on mortality and in-hospital stay. https://www.medrxiv.org/content/10.1101/2020.09.30.20204719v1 From 2933 patients in a multicenter retrospective cohort study, 257 fulfilled the inclusion and exclusion criteria. 124 patients were on corticosteroid pulses, and 133 were not.… Continue reading "(04 Oct 2020) Corticosteroids- significantly reduced mortality in severe COVID patients"

Month: October 2020